UniQure’s Glybera Is First Gene Therapy Okayed In Western Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
UniQure’s Glybera (alipogene tiparvovec) has become the first gene therapy to be approved for commercialization in the 27-nation European Union, marking a major step towards making such medicines available for treating rare diseases that have a high unmet medical need.
You may also be interested in...
Financings Of The Fortnight: IPOs Dominate Early 2014 With 13 Debuts In As Many Days
Insider participation continues to play an important role in getting a majority of biotech IPOs off the ground; and it’s not clear if or when that trend will change. Plus, news on recent financings by Dicerna, uniQure, Lumos Pharma and NightstaRx.
Deals Of The Week Looks At Pricing Conundrums
New therapeutic modalities can bring unexpected challenges in pricing, as uniQure and electroCore learn. Also, deal news from Celgene/OncoMed, Forest/Merck, Theraclone/PharmAthene, The Medicines Company/Rempex and Roche/Molecular Partners.
Viruses On The Verge Of Joining The War On Cancer
With new approaches in development that add or subtract genetic material to viruses, or arm them with immune-boosting proteins, oncolytic viruses may become the next modality for treating cancer. Several smaller companies and their backers – as well as those who have yet to invest in the space – eagerly await results from Amgen’s Phase III program OncoVex.